http://www.alensagenerics.com Connecting the generics industry Fri, 17 Jul 2009 15:19:11 +0000 http://backend.userland.com/rss092 en Lately, the generics industry has been bashed from all sides with regards to quality, with most of the criticism being directed towards poor Quality-Control standards in Chinese manufacturing facilities. But this month was a terrible one in terms of quality control for a whole bunch of otherwise top-tier generics companies ... http://www.alensagenerics.com/2009/07/17/batch-release-outsourcing-a-bad-idea/ The Wall Street Journal reported in June that according to Federal Trade Commission Chairman, Jon Leibowitz, originator pharma companies were costing consumers $3.5 billion annually through making contracts with generic companies that delay the market entry of generic versions of their drugs. The way these contracts work is that pharma companies ... http://www.alensagenerics.com/2009/07/17/authorized-generics-cost-us-consumer-35-billion-annually/ This slide by presented by Daniel Hawkins in the MM&M podcast clearly shows why there will soon no longer be a distinction between originator pharma and generic companies. Not many words needed. http://www.alensagenerics.com/2009/07/07/top-rx-sales-quickly-eroded-by-generics/ Last week's MM&M webcast titled "From Selling Pills to Selling Health Outcomes" was packed with thought provoking material. Joining the podcast were Daniel Hawkins (Clarion Healthcare Consulting), Dennis Urbaniak (Sanofi-Aventis) and Dan Rubin (inVentiv Patient Outcomes). Daniel Hawkins introduced the current market scenario as follows : the traditional pharma marketing formula; ... http://www.alensagenerics.com/2009/07/07/changing-pharma-dynamics-the-it-pharmacy/ Guest post by BullPharma (Portugal) : The world is changing, and more and more challenges are in front of the Pharmaceutical Industry. In our day-to-day business vocabulary some words are mandatory – globalization, crisis, cost reductions, downsizing, internet, back to basics, and so on. Like the “classic” half cup of water, ... http://www.alensagenerics.com/2009/04/08/ready-for-the-pharma-industry-trends/ You can't imagine our surprise today when we saw that Pfizer has announced that it will license injectable and solid dosage forms from Aurobindo. We wrote about Pfizer's new generics strategy on monday, but we definitely didn't expect this. If you had asked people in the industry ten years ago ... http://www.alensagenerics.com/2009/03/03/industry-shocker-pfizer-licenses-from-aurobindo/ "If you can't beat them, join them". So goes the old saying that is proving more true day-by-day in the pharma industry.  A few years ago it would have been unthinkable that Pfizer, the world's largest pharma company, would ever dream of relying on generics for its future. But according ... http://www.alensagenerics.com/2009/03/02/pfizer-gives-up-the-fight-and-joins-generics-bandwagon/ Two very positive announcements were made last week by Andrew Witty, chief executive of Galxo SmithKline. The first covers the price of medicines in developing nations which he said Glaxo would cap at no more than 25% of the price in the developed world. The second interesting point was the ... http://www.alensagenerics.com/2009/02/19/big-pharma-grows-a-heart/ Even as patents on huge blockbuster drugs are still expiring, the smart generics companies have been preparing for some time for a future in which there are fewer and fewer syntehsized molecules to copy and instead the race switches to copying biotech products. This is the trend behind yesterday's announcement ... http://www.alensagenerics.com/2009/01/21/competition-for-biosimilarsbiogenerics-heating-up/ Following the death of Mr. Merckle, the sale of his empire continues at a swift pace. The Independent is reporting that Phoenix UK, with a turnover of €1.2bn and controlling 15 per cent of the British drugs distribution market is up for sale with Alliance Boots, Lloyds Pharmacy and The ... http://www.alensagenerics.com/2009/01/14/merckles-phoenix-empire-crumbling-uk-operations-for-sale/